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Abstract
Purpose To investigate the choroidal
thickness using optical coherence tomography
in the eyes of patients with unilateral and
bilateral pseudoexfoliation syndrome and to
compare them with healthy controls.
Methods We studied four groups: (1)
affected eyes from 30 patients with unilateral
PEX syndrome affecting the right eye of 17
patients and the left eye of 13 patients; (2)
clinically unaffected eyes of 30 patients with
unilateral PEX syndrome; (3) the eyes of 30
patients with bilateral PEX syndrome; and
(4) the eyes of 30 normal healthy subjects.
Choroidal thickness was evaluated using
high-speed, high-resolution enhanced depth
imaging by spectral-domain optical coherence
tomography. Optical coherence tomography
features were compared in all groups using
the statistical package SPSS v 15.0.
Results The mean subfoveal choroidal
thicknesses were 237.35± 58.01 μm in group 1;
330.75± 47.84 μm in group 2; 206.3± 86.75 μm
in group 3; and 311.8± 51.42 μm in group 4.
Significant differences in the mean subfoveal
choroidal thickness were found between
groups 1 and 2 (Po0.001), groups 1 and 4
(P= 0.004), groups 2 and 3 (Po0.001), and
groups 3 and 4 (Po0.001).
Conclusion In this study, it was observed
that clinically affected eyes of patients with
PEX syndrome have significantly thinner
choroids compared with the clinically
unaffected eyes of patients with unilateral
PEX syndrome and eyes of healthy
controls.
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Introduction
Pseudoexfoliation (PEX) syndrome is a
genetically determined, age-dependent,
generalized disorder of the elastic fiber system. It
is characterized by progressive accumulation of
abnormal extracellular fibrillary material on
many ocular and extraocular tissues, including
the periphery of blood vessels.1,2 PEX syndrome
is probably due to predisposing genetic factors
and certain vascular conditions that induce tissue
hypoxia.2 Recent progress and advances have led
to improvements in clinical management by
providing a deeper understanding of the effects
of the PEX process on ocular tissues and by
increasing evidence for systemic associations of
PEX with cardiovascular and cerebrovascular
morbidity.3,4 A previous study has also shown
asymmetric values of the two carotid trees of
patients with unilateral PEX.5
In recent studies, optical coherence tomography
(OCT) was introduced as an effective tool for
evaluating choroidal thickness. Thanks to recent
technological developments, new-generation
spectral-domain (SD)-OCT devices with
enhanced scanning speed provide the
opportunity to achieve high-resolution images
and more accurate measurements. In the
enhanced depth imaging technique (EDI), scan
acquisition of the choroidal–scleral boundary is
set up adjacent to zero delay, where the
sensitivity in SD-OCT images is highest.
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Thus, it has become possible to evaluate ocular tissues
located at deeper levels than that of the retina, which
could not be evaluated with time domain OCT.6,7
There are several studies related to both ocular and
choroidal blood flow in PEX syndrome.3–5,8,9 However,
there have not been any reports to investigate choroidal
thickness in patients with PEX syndrome. Therefore, in
our study, we intended to evaluate the choroidal
thickness of patients with unilateral and bilateral PEX
syndrome and to compare them with that of healthy eyes.
Materials and methods
The eyes of the subjects were allocated to four groups:
group 1 consisted of affected eyes of 30 patients with
unilateral PEX syndrome (right eye of 17 patients and left
eye of 13 patients); group 2 consisted of clinically
unaffected eyes of 30 patients with unilateral PEX
syndrome; group 3 consisted of 30 patients with bilateral
PEX syndrome; and group 4 (control group) consisted of 30
age- and gender-matched normal subjects without PEX
syndrome. The patients in groups 1 and 2 are the same
patients. To ensure consistency, the right eyes from each
patient with bilateral PEX syndrome and control subject,
and both eyes from patients with unilateral PEX syndrome
were included. The study protocol was approved by the
Human Subjects Committee of Baskent University and
adhered to the Declaration of Helsinki. A detailed
informed consent was obtained prior to each individual’s
participation in the study. We certify that all applicable
institutional and governmental regulations concerning the
ethical use of human volunteers were followed during this
research. Patients were excluded if they had a history of
ocular surface disorder; any type of glaucoma; previous
ocular surgery or injury; history of any systemic disease
that may affect the choroidal circulation, such as
hypertension, diabetes, vasculitis, or renal failure; or if they
were being administered drugs, including analgesics,
decongestants, and antihistamines. As choroial thickness is
strongly correlated with IOP, refractive error, and axial
length;10,11 to minimize the effect of axial length and IOP
on choroidal thickness, patients with best-corrected visual
acuity worse than 20/20, a refractive error higher than 1D
and the IOP level 422mmHg were excluded from the
study. All patients underwent a complete ocular
examination conducted by the same ophthalmologist
(FCE). The examination included slit lamp biomicroscopy,
intraocular pressure measurement, gonioscopy, dilated
fundus examination, and choroidal thickness
measurements using EDI-OCT. PEX was clinically
diagnosed by the presence of typical PEX material at the
pupil border on undilated examination, on the anterior
lens capsule on dilated examination, or on the trabecular
meshwork on gonioscopy, with or without Sampaolesi’s
line and pigment deposition in the angle and/or corneal
endothelium.
Choroidal thickness measurements were performed by
the same experienced technician using a high-speed and
high-resolution SD-OCT device (λ= 840 nm, 26 000A-
scans/s, and 5 μm axial resolution), and results were
analyzed using OptovueRTVue software version 3.5
(Optovue Inc., Fremont, CA, USA). The OptovueRTVue
support ‘chorioretinal imaging mode’ was used for EDI
imaging. The scan pattern used by OptovueRTVue was
the retina cross-line, consisting of two orthogonally
oriented 6-mm lines consisting of 1024A-scans. By
automatically inverting the image, the chorioretinal
interface became adjacent to the zero delay. The retina
cross-line scan had 32 frames in average, 16 per direction,
without tracking.12
Choroidal thickness was measured perpendicularly
from Bruch’s membrane equivalent to the choroid-sclera
interface at the fovea and at 5 more points located at
500 μm nasal to the fovea, 1000 μm nasal to the fovea,
500 μm temporal to the fovea, 1000 μm temporal to the
fovea, and 1500 μm temporal to the fovea using
OptovueRTVue software’s ‘chorioretinal imaging mode’.
Choroid-sclera interface was defined as the outermost
dark-to-bright boundary (Figure 1). Choroidal thickness
measurements were performed manually by two masked
physicians (FCE and CS). If there was a difficulty to
allocate the sclera-choroid interface in an EDI-OCT scan,
the choroidal thickness measurement was excluded from
statistical analysis. All basal OCT scans were performed
at the same time of the day (in the morning) to avoid
diurnal fluctuations. The two measurements were
averaged; the differences between readings performed by
the masked physicians were found to be within 10 μm of
the mean. If the measurements did not agree within
10 μm, then they were repeated, and if the inconsistency
persisted, a third masked physician (LA) took a
measurement. Of course, there was some difficulty on few
images. But these scans were excluded from statistical
analysis if differences between readings performed by the
masked physicians were not found within 10 μm. The
interobserver reproducibility of the choroidal
measurements was evaluated by measuring the interclass
correlation coefficient (ICC).
Statistical analysis was performed using the statistical
package SPSS v 15.0 (SPSS Inc., Chicago, 2006).
Interobserver correlation (IC) was calculated for all
choroidal thickness measurements. Baseline choroidal
thickness measurements of the groups were compared by
ANOVA. The categorical variables between the groups
were analyzed using the χ2 test. Po0.05 was considered
as statistically significant.
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Results
The mean age of the patients in group 1 and 2 was
63.7± 9.1 years (range 47–80 years). Patients in group 3
had a mean age of 61.9± 9.5 years (range 44–79 years),
and those in group 4 had a mean age of 58.3± 9.4 years
(range 41–76 years). Groups 1, 2, and 3 included 16 males
and 14 females; group 4 included 17 males and 13
females. There was no statistically significant difference
regarding age (P= 0.197) and gender (P= 0.937) between
groups. Mean IOP at the time of examination was found
to be 17.2± 4.3 mmHg (range 14–21mmHg) in group 1,
16.8± 3.7 mmHg (range 12–20mmHg) in group 2,
18.3± 3.6 mmHg (range 15–22mmHg) in group 3 and
16.1± 3.2 mmHg (range 13–19mmHg) in group 4. Mean
axial length values of the patients was 23.10± 1.20mm
(range 22.12–23.91mm)in group 1, 23.21± 0.9 mm (range
22.11–23.96mm)in group 2, 23.01± 1.23mm (range 21.78–
24.21mm) in group 3, and 23.24± 1.04mm (range 22.43–
24.64) in group 4. There was no statistically difference
regarding IOP levels (P= 0.08) and axial length (P= 0.121)
between groups.
The mean subfoveal choroidal thickness was 237.35±
58.01 μm in group 1, 330.75±47.84 μm in group 2,
206.3± 86.75 μm in group 3, and 311.8±51.42 in group 4.
Significant differences in the mean subfoveal choroidal
thickness were found between groups 1 and 2 (Po0.001),
groups 1 and 4 (P= 0.004), groups 2 and 3 (Po0.001), and
groups 3 and 4 (Po0.001). The differences in mean
subfoveal choroidal thickness between groups 1 and 3
(P= 0.253) and groups 2 and 4 (P= 0.492) were not
statistically significant. Moreover, as shown in Table 1,
choroidal thicknesses of groups 1 and 3 were always
thinner than those of groups 2 and 4 in all eyes at all six
measurement points. Figure 2a–d illustrates the choroidal
thickness for an individual with bilateral and unilateral
PEX syndrome group, respectively.
The interobserver ICC reproducibility for the mean
choroidal thickness was 0.938 (95% CI, 0.931–0.984) and
ICC was 40.93 for all measurement points (Po0.001).
Table 2 shows the comparison of the mean choroidal
thickness measurements by two different observers
between groups.
Discussion
PEX has been reported as a systemic vascular disease and
is occasionally referred to as PEX vasculopathy.1,3–5
Elastin is the major part of the extracellular matrix of
arterioles and previous studies have shown an association
of vascular elastosis with pseudoexfoliative materials.
Therefore, a possible association has been hypothesized
between the presence of ocular pseudoexfoliation and
vascular diseases.1–4 In several studies it has been
reported that cerebrovascular disease, arterial
Table 1 Mean± SD (in μm) of choroidal thickness measure-
ments of groups 1, 2, 3, and 4
Group 1 Group 2 Group 3 Group 4
N2 252.45± 75.25 333.65± 67.78 207.05± 69.44 320.9± 76.61
N1 276.15± 76.88 335.05± 68.86 209.1± 75.48 311.75± 57.48
F 237.35± 58.01 330.75± 47.84 206.3± 86.75 311.8± 51.42
T1 259.35± 76.31 338.65± 48.09 199.5± 76.31 296.85± 45.22
T2 242± 76.56 321.95± 46.03 188.25± 76.12 285.3± 51.68
T3 242.4± 76.01 304.4± 49.74 182.55± 76.45 261.45± 56.55
N2: choroidal thickness at 1000 μm nasal to the fovea; N1: choroidal
thickness at 500 μm nasal to the fovea; F: choroidal thickness at fovea; T1:
choroidal thickness at 500 μm temporal to the fovea; T2: choroidal
thickness at 1000 μm temporal to the fovea; T3: choroidal thickness at
1500 μm temporal to the fovea.
Figure 1 T-1500: Choroidal thickness at 1500 μm temporal to the fovea; T-1000: Choroidal thickness at 1000 μm temporal to the fovea;
T-500: Choroidal thickness at 500 μm temporal to the fovea; F: Choroidal thickness at fovea; N-500: Choroidal thickness at 500 μm nasal
to the fovea; N-1000: Choroidal thickness at 1000 μm nasal to the fovea.
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hypertension, ischemic heart disease, and coronary artery
disease appeared to be more frequent in patients with
PEX syndrome.3,4 Repo et al13 revealed a high rate of iris
transluminance and pseudoexfoliation among patients
with transient ischemic attacks. They hypothesized that
hypoxia has an important contributory role in
pseudoexfoliation.
PEX is known as a risk factor for a wide spectrum of
ocular complications, especially secondary open-angle
glaucoma, and has also been suggested to be associated
with retinal vein occlusion (RVO).13–15 One possible
explanation for the association between PEX and RVO
might be a potential PEX vasculopathy of the retinal veins
causing thrombosis due to damaged venous vascular
endothelium.14 Iris blood vessel abnormalities are
frequently observed in patients with PEX syndrome.
A vasculopathy of iris blood vessels leading to
degeneration of vessel walls and obliteration of blood
vessels with iris hypoperfusion may be observed in PEX
syndrome.15 Moreover, reduced cerebral blood flow in
PEX syndrome has been reported previously.8
A structurally and functionally normal choroidal
vasculature is essential for retinal function. As a highly
vascular ocular structure, the choroid is directly
influenced by intraocular and perfusion pressure.
Therefore, a precise clinical evaluation of choroidal
morphology should be important for understanding the
pathogenesis of many retinal and choroidal diseases.16,17
To date, SD-OCT featuring high resolution and scanning
speeds has allowed the choroid to be assessed in vivo.12
Figure 2 Choroidal thickness measurements by enhanced depth imaging optical coherence tomography in right eye (a) and left eye (b)
of a patient with bilateral PEX syndrome and in the unaffected eye (c) and affected eye (d) of a patient with unilateral PEX syndrome.
Table 2 Comparison of the mean subfoveal choroidal thickness measurements of the group 1, group 2, group 3, group 4 between two
different observers
Group 1 Group 2 Group 3 Group 4
Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2
N2 256.15± 76.34 250.45± 72.46 335.66± 66.76 330.44± 67.18 210.34± 70.09 206.05± 69.89 324.9± 77.34 318.9± 76.18
N1 273.19± 74.28 278.23± 76.05 333.12± 67.98 336.23± 68.08 210.23± 76.23 206.1± 75.18 313.67± 55.78 309.65± 56.39
F 239.49± 61.34 234.31± 59.11 324.09± 51.45 335.12± 47.08 202.31± 80.67 208.3± 84.12 315.03± 53.23 308.81± 50.52
T1 254.43± 75.34 260.31± 76.48 335.45± 49.08 339.67± 48.29 197.15± 76.11 202.22± 74.09 293.77± 47.32 299.28± 45.67
T2 242.12± 75.58 245.87± 76.08 327.86± 45.44 320.95± 44.98 185.34± 74.13 191.22± 77.02 288.14± 50.45 285.02± 53.88
T3 241.45± 74.11 246.65± 77.09 301.19± 49.34 305± 50.23 184.53± 75.34 181.65± 74.12 258.67± 55.46 264.48± 56.02
N2: choroidal thickness at 1000 μm nasal to the fovea; N1: choroidal thickness at 500 μm nasal to the fovea; F: choroidal thickness at fovea; T1: choroidal
thickness at 500 μm temporal to the fovea; T2: choroidal thickness at 1000 μm temporal to the fovea; T3: choroidal thickness at 1500 μm temporal to
the fovea.
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Spaide et al18 described an ‘enhanced deep imaging’ (EDI)
technique to optimize the parameters of OCT allowing
full thickness choroid visualization. Since then, choroidal
thickness has been increasingly investigated in ocular
diseases, as well as in healthy eyes.19–23
In our study, OptovueRTVue software’s ‘chorioretinal
imaging mode’ was used to measure choroidal thickness.
Branchini et al12 stated that choroidal thickness might be
measured by RTVue using the ‘chorioretinal imaging
mode’. In this mode, it is possible to image the choroidal–
scleral interface by adjusting the position of the
instrument relative to the patient’s eye, such that
sensitivity to the choroid is maximized. Although
choroidal thickness was measured manually in our study,
the results showed high interobserver reproducibility.
Eyes with clinically visible PEX accumulation tend to
show higher IOP levels than normal eyes, even when
glaucoma may not be present.22 Moreover, IOP level may
influence choroidal thickness as it has been shown in the
past.11 In our study, to eliminate the effects of IOP level
over the choroidal thickness; participants with IOP level
422mmHg were not included in the study.
It has been reported that choroidal thickness increases
in patients with Voght–Koyanagi–Harada disease20 and
central serous chorioretinopathy21 or decreases in patients
with pathologic myopia,10 age-related macular
degeneration,16 glaucoma,22 and diabetic retinopathy.23
These studies speculated that abnormal choroidal
thickness may be associated with abnormal choroidal
circulation. Sogava et al24 mentioned that there was no
correlation between the choroidal thickness and choroidal
blood flow in healthy young subjects. However, in two
different studies, the authors reported that sildenafil
citrate increases choroidal thickness because of the
vasodilatory effect of sildenafil citrate on the choroidal
circulation.25,26
Histopathological studies showed that PEX
accumulations in the ocular and peribulbar tissues have
been detected not only in affected eyes, but also clinically
unaffected eyes and therefore it was stated that the so-
called unilateral PEX syndrome is clinically asymmetric
rather than truly unilateral.27 Our study showed that the
eyes of patients in the bilateral PEX group (group 3) and
the affected eyes of the patients in the unilateral PEX
group displayed choroidal thicknesses that were thinner
than those of the eyes of normal subjects (group 4) and the
unaffected eyes of the patients in the unilateral PEX group
(group 2). Interestingly, the mean choroidal thickness in
all six measurement points was found to be significantly
thinner than the fellow eye, in the eyes with clinically
apparent PEX syndrome.
PEX has been shown to affect smaller vessels rather
than the major ones.2 It accumulates in cells that have a
regulatory role for local microcirculation such as, vascular
endothelial cells, smooth muscle cells and pericytes.27
Therefore, a possible explanation for reduced choroidal
thickness, may be related to impairment local choroidal
microcirculation. Moreover, as a result of accumulation of
the PEX material in the vessel walls, vascular alterations
like increased permeability, obstruction, and loss of small
vessels have been described in the PEX syndrome.13,15
Cursiefen et al14 reported a histopathologic and
microscopic study of PEX in eyes with ischemic central
retinal vein occlusion and did not find any structural
abnormalities or PEX deposits in the retinal vessels on
electron microscopy. The same possibly might be true of
the choroidal vasculature. There are no histopathologial
studies related to choroidal vessels in the literature,
however, independent from any vascular structural
abnormalities or accumulation of the PEX material in the
choroid vessels, tissue hypoxia due to reduced carotid,
and choroidal blood flow might be responsible for thinner
choroidal thickness in PEX-affected eyes.
In 1997, Sibour et al9 studied choroid pulsatile blood
flow differences between the apparently healthy eye and
the affected eye in patients with unilateral PEX syndrome.
Interestingly, they found that the PEX-affected eye had a
flow less than that of the other eye and a mean 14% ocular
blood flow reduction in the affected eye compared with
its fellow. Moreover Scullica et al5 found reduced carotid
blood flow evaluated by ecodoppler in the PEX-affected
eye compared with the fellow eye. In our study, reduced
choroidal thickness values were detected in clinically
PEX-affected eyes, which also correlates with both
Sibour’s and Scullica’s studies. As a result, we speculated
that choroidal blood flow is not affected until the PEX
material clinically appears in the eye. In addition, reduced
carotid and choroidal blood flow owing to ipsilateral
vascular PEX material accumulation might be responsible
for decreased choroidal thickness in the PEX-
affected eyes.
The limitation of our study is that, a larger cohort study
would have allowed a more meaningful analysis on the
relation between PEX syndrome and choroidal thickness.
However, this can also be achieved in a further study
based on the preliminary findings of this study.
Moreover, the high interclass correlation coefficients
between the two physicians (ICC40.93, for all
measurement points) make the results more valuable.
In conclusion, patients with clinically PEX-affected eyes
tend to have thinner choroids than both the fellow eye
and the eyes of healthy individuals, which might be a
result of the tissue hypoxia induced by reduced choroidal
and carotid blood flow associated with this disease.
Further studies with larger groups, especially unilateral
PEX syndrome, and longer follow-up periods are
necessary to come to a more definite conclusion.
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Summary
What was known before
K There are several studies related to both ocular and
choroidal blood flow in PEX syndrome. However, there
have not been any reports to investigate choroidal
thickness in patients with PEX syndrome.
What this study adds
K Our study has concluded that choroidal thickness is
significantly decreased in clinically affected eyes with PEX
Syndrome that might support the tissue hypoxia
associated with this disease.
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